<DOC>
	<DOC>NCT00324038</DOC>
	<brief_summary>The primary objective is to compare buprenorphine transdermal delivery system (BTDS) with standard- treatment in subjects with osteoarthritis (OA).</brief_summary>
	<brief_title>Buprenorphine in the Treatment of Osteoarthritis (OA) in the Elderly</brief_title>
	<detailed_description />
	<mesh_term>Osteoarthritis</mesh_term>
	<mesh_term>Codeine</mesh_term>
	<mesh_term>Buprenorphine</mesh_term>
	<mesh_term>Acetaminophen</mesh_term>
	<criteria>Either sex aged 65 or above Diagnosis of OA of the hip and/or knee Severe pain requiring step two medication Taking maximum dose of paracetamol Painful disease of the joints other than OA Contraindication to buprenorphine, other opioids, patch adhesives or nonsteroidal antiinflammatory agents (NSAIDS) Subjects taking cyclooxygenase (COX) II selective inhibitors</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>OA</keyword>
	<keyword>Elderly</keyword>
	<keyword>Pain</keyword>
	<keyword>OA of the hips and/or knees</keyword>
</DOC>